KZIA
Income statement / Annual
Last year (2024), Kazia Therapeutics Limited's total revenue was $2.31 M,
an increase of 415,755.86% from the previous year.
In 2024, Kazia Therapeutics Limited's net income was -$26.78 M.
See Kazia Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$2.31 M |
$555.00 |
$25.00 |
$15.18 M |
$1,061.00 |
$1,565.00 |
$13,108.00 |
$8.79 M |
$4.07 M |
$89,000.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.31 M
|
$555.00
|
$25.00
|
$15.18 M
|
$1,061.00
|
$1,565.00
|
$13,108.00
|
$8.79 M
|
$4.07 M
|
$89,000.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$17.38 M
|
$15.56 M
|
$20.25 M
|
$14.54 M
|
$9.49 M
|
$6.48 M
|
$9.77 M
|
$11.14 M
|
$9.89 M
|
$5.94 M
|
| General & Administrative Expenses |
$13.56 M
|
$8.58 M
|
$4.51 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$127,043.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.56 M
|
$8.58 M
|
$4.64 M
|
$7.02 M
|
$3.69 M
|
$3.79 M
|
$5.60 M
|
$8.53 M
|
$5.76 M
|
$3.84 M
|
| Other Expenses |
-$28.64 M
|
-$22,558.00
|
-$10,000.00
|
$0.00
|
-$22,000.00
|
-$9,000.00
|
$3.67 M
|
$0.00
|
$2.87 M
|
$1.54 M
|
| Operating Expenses |
$2.31 M
|
$24.12 M
|
$24.88 M
|
$24.13 M
|
$13.16 M
|
$10.25 M
|
$14.69 M
|
$19.66 M
|
$15.64 M
|
$9.68 M
|
| Cost And Expenses |
$2.31 M
|
$24.12 M
|
$24.88 M
|
$24.13 M
|
$13.16 M
|
$10.25 M
|
$14.69 M
|
$19.66 M
|
$15.64 M
|
$9.68 M
|
| Interest Income |
$12,000.00
|
$22,558.00
|
$2,094.00
|
$42,240.00
|
$66,000.00
|
$100,000.00
|
$119,000.00
|
$276.00
|
$406,000.00
|
$89,261.00
|
| Interest Expense |
$0.00
|
$0.00
|
$2,094.00
|
$0.00
|
$0.00
|
$2.19 M
|
$0.00
|
$0.00
|
$0.00
|
$68,621.00
|
| Depreciation & Amortization |
$1.87 M
|
$1.87 M
|
$1.87 M
|
$1.27 M
|
$1.08 M
|
$1.08 M
|
$1.55 M
|
$1.41 M
|
$642,641.00
|
$574,964.00
|
| EBITDA |
-$26.77 M |
-$22.28 M |
-$23.51 M |
-$5.11 M |
-$11.11 M |
-$7.71 M |
-$10.82 M |
-$9.44 M |
-$11.72 M |
-$7.48 M |
| EBITDA Ratio |
-11.6
|
-40138.86
|
-940592.36
|
-0.34
|
-10470.77
|
-4927.16
|
-825.07
|
-1.07
|
-2.88
|
-84.02
|
| Operating Income Ratio |
0
|
-43466.61
|
-1067853.08
|
-0.42
|
-11804.9
|
-5354.63
|
-952.62
|
-1.23
|
-3.14
|
-91.47
|
| Total Other Income/Expenses Net |
-$27.05 M
|
$3.39 M
|
$0.00
|
-$2.53 M
|
-$569,576.00
|
-$1.75 M
|
$6.02 M
|
$7,870.00
|
$227,965.00
|
$754,786.00
|
| Income Before Tax |
-$27.05 M
|
-$20.74 M
|
-$25.02 M
|
-$8.91 M
|
-$12.77 M
|
-$10.57 M
|
-$6.34 M
|
-$10.87 M
|
-$12.16 M
|
-$7.31 M
|
| Income Before Tax Ratio |
-11.72
|
-37362.65
|
-1000635.8
|
-0.59
|
-12031.1
|
-6752.72
|
-483.98
|
-1.24
|
-2.99
|
-82.09
|
| Income Tax Expense |
-$271,000.00
|
$271,092.00
|
-$368,080.00
|
$484,347.00
|
-$298,000.00
|
-$298,000.00
|
-$305,000.00
|
$198,544.00
|
$2.77 M
|
$1.44 M
|
| Net Income |
-$26.78 M
|
-$20.47 M
|
-$24.65 M
|
-$8.42 M
|
-$12.47 M
|
-$10.27 M
|
-$6.04 M
|
-$10.67 M
|
-$12.06 M
|
-$7.14 M
|
| Net Income Ratio |
-11.6
|
-36874.2
|
-985912.6
|
-0.55
|
-11750.24
|
-6562.3
|
-460.71
|
-1.21
|
-2.96
|
-80.21
|
| EPS |
-55.85 |
-55.55 |
-93.05 |
-35.8 |
-81.75 |
-85.6 |
-59.8 |
-109.3 |
-135.2 |
-143.45 |
| EPS Diluted |
-55.85 |
-55.55 |
-93.05 |
-35.8 |
-81.75 |
-85.6 |
-59.8 |
-109.3 |
-135.2 |
-143.45 |
| Weighted Average Shares Out |
$479,600.00
|
$368,600.00
|
$265,000.00
|
$235,400.00
|
$152,459.00
|
$120,007.00
|
$100,959.00
|
$97,634.00
|
$89,203.00
|
$49,756.00
|
| Weighted Average Shares Out Diluted |
$479,600.00
|
$368,600.00
|
$265,000.00
|
$235,400.00
|
$152,459.00
|
$120,007.00
|
$100,959.00
|
$97,634.00
|
$89,203.00
|
$49,756.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
